SARS coronavirus 2 spike protein RBD Ab.neut:PrThr:Pt:Ser/Plas:Ord:sVNTLOINC code
Preferred Label : SARS coronavirus 2 spike protein RBD Ab.neut:PrThr:Pt:Ser/Plas:Ord:sVNT;
LOINC status : ACTIVE;
LOINC display name : SARS-CoV-2 (COVID-19) S protein RBD neut ab sVNT Ql;
LOINC long common name : SARS-CoV-2 (COVID-19) S protein RBD neutralizing antibody [Presence] in Serum or Plasma
by sVNT;
LOINC short name : SARS-CoV-2 S RBD NAb SerPl Ql sVNT;
LOINC description : Qualitative results for detection of neutralizing antibodies (NAbs) that block the
binding of the S (spike) protein receptor binding domain (RDB) from SARS Coronavirus
2 (SARS-CoV-2) to ACE2 receptor protein in serum or plasma specimens by surrogate
virus neutralization testing (sVNT), which is an immunoassay-based method. Neutralizing
antibody testing is performed to determine whether the antibodies produced after SARS-CoV-2
infection or in response to a vaccination are able to neutralize the virus and prevent
infection or re-infection. Different methods can be used to determine the presence
of neutralizing antibodies, including conventional VNT (virus neutralization test,
cVNT), pseudovirus VNT (pVNT), and surrogate VNT (sVNT). The sVNT method currently
employs purified proteins in an immunoassay-based format, takes less time to complete,
and does not require the use of live virus compared to cVNT and pVNT methods.;
Has component